Alder BioPharmaceuticals, Inc. (ALDR - Free Report) was a big mover last session, as the company saw its shares rise more than 15% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company—as the stock is now up 60.27% in the past one-month time frame.
The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Alder BioPharmaceuticals. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Audentes Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked stock in the Medical sector is Akari Therapeutics PLC (AKTX - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alder BioPharmaceuticals, Inc. Price
Alder BioPharmaceuticals, Inc. Price | Alder BioPharmaceuticals, Inc. Quote
le="text-align: justify;"> Is ALDR going up? Or down? Predict to see what others think: Up or Down.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>